Novartis is a healthcare and pharmaceutical company based in Basel, Switzerland, incorporated in 1996.

Novartis products include oncology medicines, generic and biosimilar medicines and eye care devices. The Innovative Medicine segment of the company is divided into Novartis Oncology and Novartis Pharmaceuticals. Novartis Pharmaceuticals consists of global business franchises in ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines.

Novartis Oncology

Novartis Oncology is focused on the development and manufacturing of medicines directed towards improving and extending people's lives.


Sandoz is a division of Novartis that manufactures, distributes and sells prescription medicines and pharmaceutical active substances that are not patent protected and is franchised into Retail generics, Anti-Infectives and Biopharmaceuticals.


Alcon is a division of Novartis in the eye car product field in eye care devices and vision care. Alcon’s surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery and intraocular lenses to treat cataracts and refractive errors. Alcon’s Vision Care franchise includes contact lenses and contact lens care products. Alcon’s surgical portfolio also includes equipment for performing cataract surgery.

Novartis Gene Therapies

Previously known as AveXis, Novartis Gene Therapies works to develop and commercialize gene therapies. They have a specific focus on neurological genetic diseases. Their initial gene therapy is for spinal muscular atrophy and has been approved in the United States, Japan, the European Union, and Brazil.

Novartis Institutes for BioMedical Research (NIBR)

Part of their research and development program, the Novartis Institutes for BioMedical Research (NIBR) is working on developing informatics tools for drug discovery with a focus on open-sourced software.


Habitat is a software developed to be a self-contained object storage management system. Based on Amazon Web Services, Novartis says Habitat is capable of virtually unlimited storage and can be used as a local repository for a single application or shared and used with many clients.

Yet Another Data Abstraction (YADA)

Novartis says Yet Another Data Abstraction (YADA) is a data aggregation tool capable of accessing data sets at any data source in any format and from any environment with a single URL and a single configuration. YADA is intended to be a lightweight framework for data retrieval, searching, storage, and manipulation.


OntoBrowser is a web-based application for managing ontologies. Developed by Novartis, they say the tool is intended to provide an online collaborative solution for curators to map code list terms to preferred ontology terms. OntoBrowser also offers visualization of ontologies in hierarchical or graph format, advanced search capabilities, and web service access to data.


Railroadtracks is a Python package Novartis says is intended to handle connected computation steps for DNA and RNA sequencing.

Yet Another Pipeline (YAP)

Yet Another Pipeline (YAP) is an extensible parallel framework developed by Novartis and written in Python using OpenMPI libraries. The software is intended to help researchers build high throughput data pipelines without knowledge of parallel programming.


Developed by Novartis, the RDKit is a collection of cheminformatics and machine-learning softwre written in C++ and Python. The distribution includes a PostgreSQL-based cartridge allowing molecules to be stored in a relational database and allowing users to retrieve information via substructure and similarity searches.


GridVar is a JQuery plugin that visualized multi-dimensional datasets as layers organized in a row-column format. Novartis says the software is intended to allow users to visualize data as a background color and enables characteristics of a dataset to be layered on top of each other.

Nerve Live

Developed by Novartis to use big data and data analytics, Nerve Live is an advanced analytics platform is intended to be used as part of a drug discovery program. Novartis sees the platform as enabling machine learning and cognitive computing systems to extract information which traditional data analysts and users might miss.

The Nerve Live was developed by first building a data lake. This was followed by developing an analytics engine to process the data and derive assets from it. And the final stage of development of this program involved designing user modules that would make predictive analytic insights and offer these insights to add value in business decisions.

Novartis hopes to develop Nerve Live to offer features to help manage resources, including using predictive models to plan medical supplies for medical centers.

data42 Program

The data42 program is a digital research and development platform Novartis believes will help in drug discovery and drug testing while costing less. The program would include large pools of patient and pharmaceutical data and an artificial intelligence to assist researchers in their development. As of March 2020, the program was still in the initial phases of development.


Novartis, previously called Ciba-Geigy, was one of the few pharmaceutical companies involved in tyrosine kinase inhibitor research when it began a collaboration with oncologist Brian Druker which resulted in discovery of the kinase inhibitor drug Gleevec (also known as Glivec or imatinib). Gleevec was FDA approved in 2001 to treat patients with chronic myelogenous leukemia (CML). Kinases perform phosphorylation, a mechanism that controls the activity of proteins in the cell. CML patients have a mutation causing their tyrosine kinase to be overactive, which signals cell to proliferate at a high rate, resulting in accumulation of immature white blood cells. Based on revenue, Gleevec was one of Novartis’s top ten pharmaceutical products in 2017.


Novartis Oncology drug Kisqali (ribociclib) in Phase III MONALEESA (Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety) trials, was reported in December 2018 to demonstrate efficacy and tolerability in combination with endocrine therapy in advanced breast cancer patients with visceral involvement. Kisqali (ribociclib) is a cyclin-dependent kinase inhibitor that inhibits cyclin-dependent kinase 4 and 6 (CDK4/6), proteins that when over active can promote cancer cell division and cancer growth. The drug is an orally available small molecule that acts by blocking phosphorylation of the retinoblastoma protein, which prevents cell-cycle progression. Kisqali is also in the NATALEE study, a Phase III clinical trial with endocrine therapy to treat early breast cancer.


December 1, 2020
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps.

May 15, 2020
Novartis CEO says any new corona virus vaccine will take two years.
April 20, 2020
Novartis acquires Amblyotech, a startup that combines 3D glasses and video game software to treat amblyopia, more commonly known as "lazy eye".
November 24, 2019
Novartis entered into an agreement and plan of merger with The Medicines Company to acquire the US-based biopharmaceutical company for USD 85.00 per share in cash, valuing the company at approximately USD 9.7 billion on a fully diluted equity basis.
October 1, 2019
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence.

May 9, 2019
Novartis acquires Xiidra, expanding front-of-eye portfolio.
April 1, 2019
Novartis agrees to pay $310 million, with the possibility for more later, for some assets of Boston-based IFM Therapeutics.
April 9, 2018
Novartis acquires AveXis, a gene therapy company, for $8.7 billion.
February 14, 2018
Novartis raises a $6,500,000 grant from Bill & Melinda Gates Foundation.
December 20, 2016
Swiss drug maker Novartis AG reached a definitive agreement to acquire Fort Worth, Texas-based Encore Vision, which is focused on developing a novel treatment in presbyopia, or far-sightedness.
Page 1 of 2

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Novartis Grant (money), February 2018
February 14, 2018
1 Result
Results per page:
Page 1 of 1


Acquired company
Acquisition amount (USD)
Date announced
Amblyotech acquired by Novartis
April 20, 2020
1 Result
Results per page:
Page 1 of 1



Barry X Lynn


Chris Ilsley

President, Chief Executive Officer

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Ken Londoner


Mike Ryan


prakash thombre


Stacia Danielle Sullivan


Steven Zeppenfeld


V and K Law


Further reading


Drug development gets big data analytics boost

Goran Mijuk


July 2, 2018

The data42 program shows Novartis' intent to go big on data and digital

Goran Mijuk


March 11, 2020

Documentaries, videos and podcasts





April 7, 2021
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
Nick Paul
April 6, 2021
Novartis has struck a deal with Artios Pharma to access DNA damage response (DDR) targets with the potential to enhance its radioligand therapies. Artios, which is run by some of the people behind pioneering DDR drug Lynparza, is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.
Amirah Al Idrus
March 30, 2021
Novartis is adding a group of radioligand therapies to its pipeline just one week after its radioligand treatment for prostate cancer staved off cancer progression and helped patients live longer in a phase 3 study. The Swiss pharma is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie Biosciences.
Nick Paul
March 23, 2021
A phase 3 prostate cancer clinical trial of Novaris' targeted radioligand therapy 177Lu-PSMA-617 has met both its primary endpoints. The result tees Novartis up to seek approval for a drug it picked up in its $2.1 billion acquisition of Endocyte.
Nick Paul
March 18, 2021
Aktis Oncology has raised a $72 million series A round to develop radiopharmaceutical treatments for solid tumors. The MPM Capital-founded biotech received investment from Novartis and Bristol Myers Squibb.
Ben Adams
March 15, 2021
Novartis is kick-starting a new trial with Molecular Partners for an experimental COVID-19 drug just a few months after another partnered attempt flopped.
Research and Markets
March 4, 2021
/PRNewswire/ -- The "Connected Drug Delivery Devices Market Size, Share & Trends Analysis Report by Technology (Bluetooth, NFC), by Product (Connected Sensors,...
March 4, 2021
The electrification of the corporate fleet, integrated solutions for charging electric vehicles (EV) and a monitoring platform for installed EV chargers are just some of the activities that form part of the partnership between Enel X and Novartis, which is set up to promote the use of electric mobility in Italy. Enel X is the Enel Group's global business line that designs and develops solutions focused on the principles of sustainability and circular economy, to provide people, communities...
March 2, 2021
/PRNewswire/ -- GENIXUS, a pharmaceutical company focused on transforming acute and critical care medicines, today announced the addition of two new members to...
Ben Adams
February 18, 2021
A major group of pharma and charitable groups have joined forces to raise a $300 million venture round for Adjuvant Capital as it goes after forgotten diseases across the globe.
Adjuvant Capital
February 18, 2021
/PRNewswire/ -- Adjuvant Capital today announced an oversubscribed $300 million fund focused on accelerating the development of medical innovations for...
Amirah Al Idrus
February 17, 2021
Novartis is adding sickle cell disease to its gene therapy stable through a partnership with the Bill & Melinda Gates Foundation. The latter will support a research team at the Swiss Pharma dedicated to discovering and developing a one-and-done in vivo treatment that can be given easily to patients all over the world.
Spherix Global Insights
February 17, 2021
/PRNewswire/ -- Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class...
Allison DeAngelis
February 16, 2021
Business Insider
Coronaviruses will remain part of our lives forever. Drug companies are exploring ways to address COVID-19 and similar viruses.
Sai Life Sciences
February 16, 2021
/PRNewswire/ -- Sai Life Sciences, una de las organizaciones de investigación, desarrollo y fabricación por contrato (CRDMOs) de más rápido crecimiento de la...
Spherix Global Insights
January 29, 2021
/PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and...
Ben Adams
January 12, 2021
This time last year, the life science world descended into San Francisco for the 2020 J. P. Morgan healthcare conference, doing the normal things like blowing a whole year's budget in one day for a hotel room, shaking hands, doing deals and, if you're like us, asking questions.
Arlene Weintraub
January 4, 2021
Activating the immune pathway STING creates an inflammatory environment that should improve immuno-oncology treatments, but clinical trials have been disappointing so far. A University of North Carolina team has promising evidence that combining CAR-T cells with STING agonists could be effective in solid tumors.
Beyeonics Surgical
December 22, 2020
/PRNewswire/ -- Beyeonics Surgical is a medical technology company developing surgeon-centered visualization solutions. Operating from Israel, the company...
Amirah Al Idrus
December 17, 2020
Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent's pipeline in a deal worth $210 million up front but that could net the latter up to $770 million in total.


Page 1 of 3
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.